Remus Pharmaceuticals (NSE:REMUS) Total Liabilities: ₹1,909 Mil (As of Mar. 2026)


NSE:REMUS Remus Pharmaceuticals Ltd NSE:REMUS
53 GF Score
Price ₹780.00
GF Value ₹2,071.36
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Remus Pharmaceuticals Total Liabilities?

Remus Pharmaceuticals NSE:REMUS -0.89% 53 Total Liabilities is ₹1,909 Mil as of Mar. 2026. GuruFocus rates NSE:REMUS with a GF Score™ of 53/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Remus Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was ₹1,909 Mil.

Remus Pharmaceuticals's quarterly Total Liabilities increased from Mar. 2025 (₹1,500.90 Mil) to Sep. 2025 (₹2,302.30 Mil) but then declined from Sep. 2025 (₹2,302.30 Mil) to Mar. 2026 (₹1,909.20 Mil).

Remus Pharmaceuticals's annual Total Liabilities declined from Mar. 2024 (₹1,579.00 Mil) to Mar. 2025 (₹1,500.90 Mil) but then increased from Mar. 2025 (₹1,500.90 Mil) to Mar. 2026 (₹1,909.20 Mil).

Remus Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Remus Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remus Pharmaceuticals Total Liabilities Chart

Remus Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial 94.78 158.50 1,579.00 1,500.90 1,909.20

Remus Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,579.00 985.40 1,500.90 2,302.30 1,909.20
NSE:REMUS
53GF Score
Remus Pharmaceuticals Ltd NSE:REMUS
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Remus Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Remus Pharmaceuticals's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1491+(86.9+331.3
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1,909

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=5786.5-3877.3
=1,909

Remus Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1491+(86.9+331.3
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1,909

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=5786.5-3877.3
=1,909

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ₹1,909 Mil mean?
Remus Pharmaceuticals (NSE:REMUS) has a Total Liabilities of ₹1,909 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Remus Pharmaceuticals and its competitors.
Is Remus Pharmaceuticals' Total Liabilities too high?
Remus Pharmaceuticals' current Total Liabilities is ₹1,909 Mil. Overall, Remus Pharmaceuticals has a GF Score™ of 53/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Total Liabilities compare to MCK and CAH?
Remus Pharmaceuticals' Total Liabilities of ₹1,909 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Distribution company?
A good Total Liabilities depends on the Medical Distribution industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Remus Pharmaceuticals and its competitors. Remus Pharmaceuticals's current Total Liabilities is ₹1,909 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹780.00 — trading 62.3% below its estimated fair value. The current Total Liabilities is ₹1,909 Mil. Remus Pharmaceuticals' overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Total Liabilities is ₹1,909 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?

Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued. The current stock price of ₹780.00 is trading 62.3% below its estimated GF Value™ of ₹2,071.36. GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for NSE:REMUS:

  • Total Liabilities: ₹1,909 Mil
  • GF Value™: ₹2,071.36 vs. price of ₹780.00 (62.3% below fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Remus Pharmaceuticals Business Description

Address Ambli bopal Road, 1101 to 1103, South Tower, One 42, Behind Ashok Vatika, Near Jayantilal Park BRTS, Ahmedabad, GJ, IND, 380054
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
53GF Score

Get the complete analysis for NSE:REMUS

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹780.00
Price
₹2,071.36
GF Value